Silo Pharma, Inc. (SILO)
NASDAQ: SILO · IEX Real-Time Price · USD
2.460
-1.010 (-29.11%)
At close: Jul 19, 2024, 4:00 PM
2.600
+0.140 (5.69%)
Pre-market: Jul 22, 2024, 7:47 AM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $72.10K in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $18.03K. In the year 2023, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
125.79
Revenue / Employee
$24,034
Employees
3
Market Cap
9.07M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72.10K | - | - |
Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
Dec 31, 2021 | 71.26K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 40.57K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 49.84K | 2.70K | 5.72% |
Dec 31, 2015 | 47.14K | 26.58K | 129.23% |
Dec 31, 2014 | 20.57K | 19.94K | 3,190.40% |
Dec 31, 2013 | 625.00 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molecular Templates | 31.76M |
Zhongchao | 19.43M |
PAVmed | 3.02M |
Elevai Labs | 2.18M |
Mangoceuticals | 844.87K |
Nexalin Technology | 158.86K |
Bionomics | 15.00K |
SILO News
- 2 days ago - Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 days ago - Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug - Benzinga
- 3 days ago - Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 - GlobeNewsWire
- 5 days ago - Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday? - Benzinga
- 6 days ago - Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic - GlobeNewsWire
- 25 days ago - Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety - GlobeNewsWire
- 6 weeks ago - Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia - GlobeNewsWire
- 6 weeks ago - Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire